Sumitomo Pharma America, Inc.

Quick facts

Marketed products

• Arformoterol and Tiotropium
• Arformoterol Tartrate Inhalation Solution · Respiratory / Pulmonology
  Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
• ciclesonide nasal aerosol · Allergy/Immunology
  Ciclesonide is an inhaled corticosteroid that reduces inflammation in the nasal airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.
• Eszopiclone (Lunesta) · Neurology / Sleep Medicine
  Eszopiclone is a nonbenzodiazepine hypnotic that binds to GABA-A receptors in the brain to promote sleep onset and maintenance.

Phase 3 pipeline

• APL-130277 · Neurology
  APL-130277 is a subcutaneous apomorphine formulation that acts as a dopamine agonist to provide rapid symptom relief in Parkinson's disease.
• Arformoterol 25 ųg BID · Respiratory
  Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
• Formoterol 12 ųg BID · Respiratory
  Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
• Levalbuterol HCl Inhalation Solution · Respiratory
  Levalbuterol is a selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve breathing.
• Levalbuterol tartrate HFA MDI · Respiratory
  Levalbuterol is a selective beta-2 adrenergic receptor agonist that relaxes airway smooth muscle to improve breathing.
• levalbuterol tartrate MDI · Respiratory
  Levalbuterol tartrate is a long-acting beta2-adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.
• Levalbuterol UDV TID · Respiratory
  Levalbuterol is a selective beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing in patients with obstructive airway disease.
• Lurasidone 20, 40, 60, 80 mg, flexibly dosed · Psychiatry
  Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.
• Lurasidone HC1 · Psychiatry
  Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.
• mometasone nasal inhalation · Respiratory
  Mometasone is a corticosteroid that works by inhibiting the release of pro-inflammatory cytokines and mediators.
• Placebo plus Dexamethasone HFA · Respiratory/Immunology
  Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
• Racemic Albuterol · Respiratory
  Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing.
• racemic albuterol MDI · Respiratory
  Racemic albuterol is a beta-2 adrenergic agonist that relaxes airway smooth muscle to relieve bronchospasm and improve airflow in obstructive airway diseases.
• Salmeterol MDI · Respiratory
  Salmeterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
• subcutaneous apomorphine · Neurology
  Subcutaneous apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to rapidly relieve motor symptoms of Parkinson's disease.

Phase 2 pipeline

• AC-3933
• APO-go · Hematology
  APO-go is a medication used to treat iron deficiency anemia.
• Racemic formoterol
• SEP-225289
• SMP-986

Phase 1 pipeline

• [14C]-DSP-5336
• azoles · Other
• DSP-0390
• DSP-1349M
• DSP-5336
• DSP-8658
• Nusivertib · Other
• SEP-228432
• SMP3124LP
• TP-1454 monotherapy
• TP 3654
• WT2725

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sumitomo Pharma America, Inc. portfolio CI brief
• Sumitomo Pharma America, Inc. pipeline updates RSS